15 stories found
Investors are being notified of class action securities fraud lawsuits filed against Insulet Corporation, HDFC Bank, Capricor Therapeutics, Wix.com, and Flotek Industries, with deadlines to lead the cases approaching.
ClaimsFiler has reminded investors of Capricor Therapeutics, Inc. (CAPR) who have incurred losses over $100,000 about the lead plaintiff deadline in an ongoing class action lawsuit.
The positive outlook for Deramiocel is strengthening Capricor Therapeutics, Inc. (CAPR) as a small-cap stock. This development positions CAPR as a potential buy.
Multiple companies, including Atour Lifestyle Holdings and National Vision Holdings, are either previewing their Q1 and Q2 2026 financial results or have already reported their GAAP EPS and revenue. This cluster covers a range of corporate earnings updates for the specified quarters.
Law firms have announced shareholder class action deadlines for both Capricor Therapeutics and Pentair plc following significant stock declines. Investors who suffered substantial losses are being encouraged to consider leading or joining the respective securities fraud lawsuits.
Alvotech shares advanced significantly, continuing a post-earnings rally, while Capricor Therapeutics and Inwit also experienced rallies. These movements indicate positive market reactions to recent company developments or earnings reports.
Kaos Capital is actively pushing for significant board changes at Capricor Therapeutics, urging shareholders to support their proposals. The investment firm is seeking to influence the company's leadership and strategic direction.
Capricor Therapeutics has announced an August 22, 2026, PDUFA date for its drug deramiocel. The company aims for a manufacturing capacity to treat 2,000 to 2,500 patients per year.
Capricor Therapeutics' stock experienced a decline following the announcement of a lawsuit filed against Nippon Shinyaku. The legal action has impacted investor confidence in Capricor.
Aprea Therapeutics stock recorded a second consecutive surge, jumping another 22%, while Capricor Therapeutics also saw its stock surge following an upgrade from Oppenheimer. These movements indicate positive investor sentiment for both pharmaceutical companies.
The U.S. Food and Drug Administration (FDA) has extended the PDUFA target action date for Capricor Therapeutics' Biologics License Application (BLA) for deramiocel to November 22. This extension allows the FDA more time to complete its review of the drug.
Capricor Therapeutics' stock experienced a decline after a report indicated a potential rejection of its drug Deramiocel, impacting investor confidence.
This article provides key highlights from Capricor Therapeutics' first-quarter earnings call, detailing financial performance and business updates.
Capricor Therapeutics signals potential commercialization of its drug Deramiocel, backed by a $318 million cash balance and an ongoing FDA review milestone.